Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating
I'm PortAI, I can summarize articles.
Analyst Charles Zhu of LifeSci Capital maintains a Buy rating on Kura Oncology, citing promising clinical data from the KOMET-007 trial and strategic partnerships. The trial shows competitive response rates and a favorable safety profile for ziftomenib. The Phase 3 KOMET-017 trial and partnership with Kyowa Kirin further support the positive outlook. Bank of America Securities also maintains a Buy rating with a $30 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments